MDGL - Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc Logo

MDGL - Madrigal Pharmaceuticals Inc

https://www.madrigalpharma.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

52W High
$443.00
52W Low
$200.63
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
-1.03
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-8.32
EV/Revenue (<3 favorable)
17.41
P/S (TTM) (<3 favorable)
18.72
P/B (<3 favorable)
13.86
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
7.67%
Institutions (25–75% balanced)
107.92%
Shares Outstanding
22,289,000
Float
10,980,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
515,547,000
Gross Profit (TTM)
496,372,000
EPS (TTM)
-12.64
Profit Margin (>10% good)
-0.55%
Operating Margin (TTM) (higher better)
-0.22%
ROE (TTM) (>15% strong)
-0.36%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
13.54
Momentum
Bearish momentum
Value
26.2727
Previous
28.5496
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025